Itonis Pharmaceuticals Appoints New Scientific Officer To Guide Clinical Process For Homeopathic Products
12/9/2013 11:13:55 AM
Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® cold remedy, are pleased to announce today the addition of Ernesto Barron to Dr. Hensley's product development team. Mr. Barron will serve as Itonis Phamaceuticals' Chief Scientific Officer and Director of Clinical Research.
"Mr. Barron is a strong addition to the team," commented Dr. Hensley. "I am excited to have him on board as he has been instrumental in the success of several of my previous products and companies."
Mr. Barron currently manages the USC/Norris Cell and Tissue Imaging Core and the Doheny Eye Institute Specialized Microscopy Core, and serves as a research coordinator for the Beckman Macular Research Center located in the Doheny Eye Institute. He also co-authored the Zicam® Zinc Nasal Gel study and conducted the efficacy study on the Zicam® allergy relief nasal gel.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.